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Background: Adhesion receptors have important role in cellular invasiveness and L-selectin is a primary
determinant in the binding of chronic lymphocytic leukemia (CLL) cells to several glycated proteins on endo-
thelial cells. We investigated L-selectin expression on CLL cells and explored the mechanisms that lead to
their shedding.
Methods: Surface and soluble L-selectin expression levels were studied by ﬂow cytometry and immunoas-
say, respectively. Magnetically isolated B-cells from patients and controls were investigated for total and pro-
tein phosphatase-2A activities. Flow cytometry of permeabilized cells was utilized for the determination of
phosphorylated mitogen-activated protein kinase (pp38MAPK) and surface tumor necrosis factor alpha-
converting enzyme expression (TACE).
Results: In CLL patients elevated absolute lymphocyte cell counts, high soluble and low surface L-selectin
expression were observed. Similarly, TACE surface expression was signiﬁcantly lower on B-CLL cells compared
to normal B-cells. Both total phosphatase and protein phosphatase-2A activities were also signiﬁcantly lower
in B-CLL cells compared to normal B-cells and we found a consequently higher level of pp38 MAPK in B-CLL
cells. Based on in vitro experiments a MAPK inhibitor could attenuate the phosphatase inhibitor’s effect on
L-selectin shedding.
Conclusions: The lower phosphatase activity detectable in chronic lymphocytic leukemia, results in a down-
stream signaling cascade with subsequent reduction of surface L-selectin expression and this effect is medi-
ated by enhanced phosphorylation of p38MAPK and an altered TACE expression. © 2019 The Authors. Cytometry
Part B: Clinical Cytometry published by Wiley Periodicals, Inc. on behalf of International Clinical Cytometry Society.
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Chronic lymphocytic leukemia (CLL) is a common
and rather heterogeneous disorder, characterized by
progressive accumulation of immunologically incompe-
tent B-lymphocytes with autonomous B cell receptor
(BCR) activation in the bone marrow (BM), blood and
lymphoid organs. Most CLL patients do not entail treat-
ment until evident progression of the disease. Mere
staging by Binet or Rai criteria is not satisfactory to
anticipate the clinical course (1).
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Numerous adhesion molecules apparently contribute
to the cellular processes involved in CLL pathogenesis,
via inﬂuencing homing of CLL cells to lymphoid organs,
survival, and proliferation (2). Leukocytes use a multi-
step adhesion cascade consisting of rolling, sticking, and
crawling to ﬁrmly adhere and transmigrate into tissues
(3). The lymphocytes ﬁrst undergo chemokine-induced
activation of their integrins, which mediate lymphocyte
arrest (4,5). Activation of leukocytes leads to shedding
of L-selectin (CD62L) from the cell surface, and this may
facilitate detachment of leukocytes from endothelium as
they migrate into the tissues. Both the low levels of cell
surface L-selectin and high level of soluble L-selectin can
account for impaired rolling and migration ability of leu-
kocytes in vivo (6–8). Cell surface L-selectin expression
that participates in B-cell homing to lymph nodes and
other secondary lymphoid organs is likely to be also
important for CLL cell migration, chemokine and
integrin-mediated adhesion, and transendothelial migra-
tion. These processes are central in trafﬁcking and reten-
tion of hematopoietic cells in the BM and lymphoid
organs. L-selectin is profoundly overexpressed on malig-
nant B-cells located within the lymph nodes and the BM
particularly in the proliferation centers.
In vitro BCR activation results in downregulation of
cell surface L-selectin on CLL cells, in particular on cells
from patients with unfavorable prognostic factors and
at risk of disease progression. In progressive cases,
BCR-responsive CLL cells within the lymph nodes are
trapped by the BCR-mediated signaling pathway and
are prone to proliferate, resulting in enlarged lymph
nodes. Conversely, BCR-unresponsive CLL cells are able
to exit rapidly from the lymphoid organs and recircu-
late, as most normal B-cells do. The dysregulation of
L-selectin expression on CLL cells is likely to contribute
to the pathological disturbance in total CLL cell number
and the accumulation of pathological B-cells in the
peripheral blood and lymph nodes (9,10). Gu et al.,
already in 2001 (11–13) showed that in advanced
B-CLL, L-selectin expression on malignant cells is less
than half than on normal peripheral blood lymphocytes
and lower levels of L-selectin expression on CLL cells
has been associated with impaired transendothelial
migration. Compared to soluble P- and E-selectin levels,
soluble L-selectin concentration is at least 20-fold
higher (6) and this value can further be increased in
pathological disorders. Here, we investigated untreated
CLL cases and conﬁrmed the downregulation of cell
surface L-selectin on circulating CLL cells. We highlight
a possible molecular mechanism leading to decreased
surface L-selectin expression and to enhanced shedding
that results in increased soluble L-selectin levels.
MATERIALS AND METHODS
Antibodies and Reagents
The following directly conjugated monoclonal anti-
bodies, isotype control, Quantibrite™ PE ﬂuorescence
quantitation kit, and Phosﬂo™ reagents were purchased
from Becton Dickinson (San Jose, CA): Mouse IgG2a-
FITC, CD5-PerCPCy5.5, CD62L-PE, Mouse anti-p38MAPK
(pT180/pY182)-PE. CD19-PC7 was from Beckman
Coulter (Indianapolis, IN) and anti-hTACE/-FITC was pur-
chased from R&D Systems (Minneapolis, MN). Paraforal-
dehyde (PFA), dimethylsulfoxide (DMSO), Histopaque
1077, and Protein G Sepharose were from Sigma-Aldrich
(St. Louis, MO). Calyculin-A (CLA) and SB203580 were
ordered from Calbiochem (La Jolla, CA) and R&D Systems
(Minneapolis, MN), respectively. Human B cell separation
kit was purchased from Life Technologies (Oslo, Norway,
Dynabeads® Untouched Human B cell). Soluble L-selectin
and soluble ADAM17/TACE were measured from
plasma using commercially available enzyme-linked
immunoassay (Bender Med System and Cloud-Clone
Corp., Houston, TX). Antibodies for immunoprecipita-
tion and Western blot were purchased R&D Systems
(Minneapolis, MN). Avidin-biotin complex kit was
from Vector Laboratories (Burligame, CA).
Patients and Controls
Blood was drawn into EDTA tubes (K2EDTA, Becton
Dickinson vacutainer tube, San Jose, CA) from a total
number of 117 untreated CLL patients including
84 patients in the observational group and an addi-
tional 33 patients in the investigative group, who were
recruited at the Division of Hematology, Department of
Internal Medicine at the University of Debrecen.
Informed consent was obtained from all participants in
accordance with the regulations set by the Ethics Com-
mittee of the University of Debrecen (registration num-
ber: 4674–2016). All patients examined in this series
had immunophenotypically deﬁned CLL as outlined by
the NCI criteria. Healthy volunteers as controls were
recruited from the staff of the Department of Labora-
tory Medicine.
Puriﬁcation of Normal B-Cells and CLL Cells
Normal and leukemic B-cells were puriﬁed from
peripheral blood. Brieﬂy, peripheral blood mononuclear
cells (PBMC) were separated on Histopaque-1077 than
normal B-cells and leukemic B-cells of CLL patients were
isolated by a magnetic Untouched Human B Cell Separa-
tion kit. In case of normal B-cell separation, the kit was
used according to the manufacturer’s instructions. We
obtained an >94% purity of CD19+ lymphocytes as deter-
mined by ﬂow cytometry. Some modiﬁcations were
applied for the separation of B-CLL cells and the purity
of the cell suspension was >98%.
Hematology Analysis, Labeling, and Flow Cytometric Assays
Peripheral blood cell count was performed according to
our routine clinical laboratory procedure on ADVIA
120 hematology analyzer (Siemens, Forcheim, Germany).
For the analysis of cell surface L-selectin and TACE
expression of normal B-cells and CLL cells, we used a
four-color staining. CD19-PC7 and CD5-PerCPCy5.5
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antibodies were used for cell identiﬁcation. We used
FITC-labeled TACE and PE-conjugated CD62L monoclo-
nal antibodies for detection of cell surface expression
of TACE and L-selectin. Mouse IgG2a-FITC was used as
an isotype control for the investigation of TACE expres-
sion. A quantitative ﬂow cytometric determination of
cell surface L-selectin was carried out by a direct immu-
noﬂuorescence assay using Quantibrite™ PE ﬂuores-
cence quantitation kit. Results were expressed as
antibody binding capacity (ABC). Cells were labeled for
30 min at room temperature (RT) in dark. Then, they
were washed twice with PBS and ﬁnally were ﬁxed in
500 μL 1% PFA.
Pp38MAPK expression was detected by ﬂow cytome-
try according to the following procedure. PBMCs were
stained with cell surface markers and were immediately
ﬁxed with BD Phosﬂow™ Fix buffer I. in a 37C water
bath for 10 min. Thereafter, cells were washed with BD
Phosﬂow™ Perm/Wash buffer I. and resuspended cells
were stained with Mouse Anti-pp38 MAPK (pT180/
pY182)-PE antibody for 30 min at RT in dark. After
washing cells were resuspended in BD Pharmingen™
Stain buffer. In each experiment, 30,000 events were
collected by an FC500 ﬂow cytometer and results were
analyzed with the Kaluza software (Beckman Coulter).
Plasma Preparation and Measurement of Soluble Proteins
Plasma from patients with CLL and healthy volunteers
were separated from K2EDTA- anticoagulated blood
by centrifugation at 1,000g for 15 min at RT. Soluble
L-selectin and soluble TACE were measured from plasma
samples using commercially available enzyme-
linked immunoassay according to the manufacturer’s
instruction.
Immunoprecipitation and Western Blot Analysis of Soluble
L-Selectin
Brieﬂy, plasma of CLL patients was puriﬁed from
immunglobulins by Protein G Sepharose for 2 h at 4C.
After centrifugation anti-human L-selectin antibody and
another aliquot of Protein G Sepharose were added to the
supernatant of the immunglobulin free plasma. Immuno-
precipitation was done overnight at 4C. After washing,
precipitates mixed with Loading Dye (61.90 mM TRIS, 2%
SDS, 10% glycerol, 0.025% bromphenol blue) were boiled
for 5 min. Samples were applied to SDS-PAGE using 10%
polyacrylamide gel. Proteins were blotted to nitrocellulose
membrane that was blocked in 3% gelatin. Subsequently
the membrane was incubated with biotinylated anti-
human L-selectin antibody for 90 min followed by avidin-
biotin complex for 60 min. Bands were visualized by
enhanced chemiluminescence (ECL).
Protein Phosphatase Assay
Magnetically separated normal B-cells and CLL-B
cells (5 × 105) were suspended in lysis buffer contain-
ing 50 mM Tris–HCL (pH 7.4), 150 mM NaCl, 1% Triton
X-100 and 0.5% protease inhibitor cocktail. The lysate
was sonicated, and then centrifuged at 15,000g at 4C
for 10 min. The phosphatase activity of the superna-
tants was determined at 30C using 1 μM 32P-labeled
20 kDa light chain (32P-MLC20) of turkey gizzard myo-
sin as substrate in the absence or presence of PP1
inhibitor-2 (I-2, 2 μM) as previously described (14). The
reaction was initiated by addition of the substrate and
after 10 min incubation was terminated by the addition
of 10% TCA and 6 mg/ml BSA. Following centrifuga-
tion, the released 32Pi was determined from the super-
natant in a scintillation counter (Perkin Elmer). The
total phosphatase activity in normal B-cells was
regarded as 100%.
In Vitro Experiment with CLA and p38MAPK Inhibitor
These experiments were carried out in suspension of
magnetically separated normal B-cells and B-CLL cells.
Cells were incubated with DMSO or CLA in different
concentrations at 37C for 30 min. For those experi-
ments, where we wanted to inhibit p38MAPK, cells
were preincubated with 5 μM SB203580—as speciﬁc
inhibitor of p38MAPK—before CLA treatment. After
treatments pp38MAPK level and surface L-selectin were
examined as describe above.
Statistical Analysis
GraphPad Prism 4.0 program was used for the statis-
tical analysis. The statistical signiﬁcance of the differ-
ences between groups was determined by unpaired
Student’s t-test in case of Gaussian distribution, and by
Mann–Whitney test in case of non-Gaussian distribu-
tion, as appropriate. Differences were considered sig-
niﬁcant when P value was below 0.05.
RESULTS
Surface and Soluble L-Selectin Expression
Peripheral blood samples of CLL patients were exten-
sively characterized by 8-color immunophenotyping. In
case of CLL patients, surface L-selectin analysis was
conducted on CD5+/CD19+ B-CLL cells while in control
samples L-selectin expression was investigated on
CD5−/CD19+ normal B-cells (Fig. 1). We have found
that surface L-selectin was signiﬁcantly reduced on
B-CLL lymphocytes in RAI 0 stage of CLL, compared to
normal B-cells. Simultaneously soluble L-selectin was
signiﬁcantly elevated in the plasma of B-CLL patients
(Fig. 2A,B), but when the soluble L-selectin level of
plasma of CLL patients was normalized for 106 leuko-
cyte counts, soluble L-selectin values became lower in
CLL patients (Fig. 2C). In cases of patients, where abso-
lute lymphocyte count was above 32 G/L, B-CLL cells
expressed low surface L-selectin levels and at the same
time plasma samples derived from these patients dis-
played elevated soluble L-selectin values (Fig. 2D,E).
L-selectin expression on T-cells in the CLL group was
similarly lower but the differences was less pronounced
(Fig. 3A). The soluble form of L-selectin can derive
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from both lymphocytes and neutrophils as could be
detected in samples containing considerable number of
neutrophils (Fig. 3B). Nevertheless, since the mean
neutrophil count in the investigated samples was
4.5 G/L, this represented a neglectable quantity com-
pared to the mean absolute lymphocyte count
(43.6 G/L). By ﬂow cytometry 78% of these lympho-
cytes were B-CLL cells, thus soluble L-selectin repre-
sented primarily the B-CLL cell derived protein.
TACE Expression and pp38MAPK Level
TACE expression was signiﬁcantly lower on the sur-
face of CD5+/CD19+ malignant B-cells while pp38MAPK
level was signiﬁcantly higher in these cells compared to
normal B-cells as determined in permeabilized cells using
a phospho-speciﬁc antibody (Fig. 4A–D).
Protein Phosphatase Activity
Phosphatase activity of B-CLL and normal B-cell
lysates was assayed in the absence and presence of PP1
inhibitor-2 (I2), accordingly total and PP2A phospha-
tase activities (the activity in the presence of I2) were
determined. We have found that both total and PP2A
phosphatase activities were signiﬁcantly lower in B-CLL
cells compared to normal B-cells (Fig. 5).
In Vitro Studies with a Phosphatase Inhibitor CLA
Leukemic B-cells from CLL patients showed higher
basic pp38MAPK level compared to normal B-cells,
after CLA treatment the pp38MAPK level was elevated
in a dose-dependent manner in both groups but the
pp38MAPK level was higher in B-CLL cells compared
to normal B-cells at all investigated CLA concentra-
tions (Fig. 6A). Similarly, a rapid downregulation of
L-selectin was observed by CLA treatment with differ-
ent kinetics in the two groups. In case of malignant
B-cells, L-selectin almost entirely was shed from the
cell surface at 10 nM CLA concentration (Fig. 6B).
L-Selectin Shedding Is Mediated via the p38MAPK
Phosphorylation in Normal B-Cell
Normal B-cells were preincubated with a highly spe-
ciﬁc inhibitor of p38MAPK (SB203580) at 5 μM concen-
tration before CLA treatment. The p38MAPK inhibited
cells showed decreased level of pp38MAPK after CLA
treatment and 5 μM SB203580 almost completely inhib-
ited the CLA induced phosphorylation of p38MAPK at
5 nM CLA concentration (data not shown). Similarly to
this change the CLA-induced shedding of L-selectin was
also attenuated at 5 nM CLA by p38MAPK inhibitor, as
depicted in Figure 6C.
FIG. 1. Expression of L-selectin (CD62L) by normal B-cells and B-CLL cells. Flow cytometry dot-plots of peripheral blood (PB) lymphocytes from a
healthy donor (panels A and B) and of a PB sample from a B-CLL case (panels C and D). CD19+ normal B-cells marked by circular gates on panels A
and B show high and homogenous CD62L expression (MFI: 60) when compared to the heterogenous and much lower CD62L expression (MFI: 12) of
the CD5+ B-CLL lymphocytes which are in rectangle gates on panels C and D. Black dots on panel D were residual normal B-cells of B-CLL sample.
[Color ﬁgure can be viewed at wileyonlinelibrary.com]
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DISCUSSION
Reversible protein phosphorylation is essential for a
myriad of biochemical processes and in a healthy state
it is tightly controlled by a network of protein kinases
and protein phosphatases. In numerous hematological
malignancies, unrestricted activation of oncogenic kinases
occur that can either be achieved by the constitutive
activation of the upstream kinases or via the inactivation
of their antioncogenic phosphatases. Functional defects
of PP2A in leukemias are due to the overexpression of
FIG. 2. Cell surface and soluble L-selectin (sLsel) analysis of B-CLL samples. L-selectin was signiﬁcantly reduced (P < 0.0001) on B-CLL
lymphocytes, compared to control B-cells and L-selectin ABC was the lowest in progressing cases (panel A). The numbers of patients in the Rai groups
were the followings: Rai 0: 27, Rai 1: 12 and in the pooled Rai 2–4: 12. Rai 2–4 patients were pooled in one group due to the low number of cases.
Contrary to surface L-selectin, soluble L-selectin was signiﬁcantly elevated in the plasma of B-CLL patients (panel B), but when these data were
normalized for leukocyte counts, soluble L-selectin values became lower in CLL patients (panel C). Patients where an absolute lymphocyte count was
above 32 G/L expressed low surface and high soluble L-selectin levels (panels D and E, respectively).
FIG. 3. Cell surface L-selectin on T-cells and soluble L-selectin in plasma of CLL patient. T-cells from CLL patients (n = 28) show signiﬁcantly lower
L-selectin expression compared to T-cells from controls (n = 15) on panel A. The soluble form of L-selectin can derive from lymphocytes and
neutrophils too. Western blot image illustrates soluble L-selectin in case of two CLL samples (panel B). Lane 1 displays a CLL sample that contain 55%
B-CLL cells and 42% neutrophils (upper band neutrophil derived, lower band lymphocyte derived L-selectin). Lane 2 shows soluble L-selectin from a
patient with 89% B-CLL cells and 5% neutrophils.
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proto-oncogenic PP2A inhibitors termed CIP2A (Cell Pro-
liferation Regulating Inhibitor of Protein Phosphatase 2A)
and SET; a putative oncoprotein in several leukemias (15).
The SET oncoprotein has been long known to be associ-
ated with myeloid malignancies (16) and later it was also
described that chronic lymphocytic leukemias and related
non-Hodgkin lymphoma cell lines also signiﬁcantly over-
express SET (17). There are several ways how SET may
inﬂuence the development of malignancies, but it is pri-
marily thought to be attributed to the inhibition of PP2A.
More recently, another important mechanism, the
enhanced oncogenic signaling by the tyrosine kinase Lyn
has been described in CLL that strengthens the SET-
mediated inhibition of PP2A (18). PP2A is involved in the
regulation of several oncogenic signal transduction path-
ways including cell transformation (19). Disease progres-
sion is mediated by several mechanisms and one aspect in
CLL is the expression of adhesive receptors on the surface
of leukemic cells.
The primary aim of this work was to delineate mech-
anisms that determine surface expression of L-selectin
in CLL and to elucidate the regulatory mechanisms of
this adhesive protein on lymphocytes. CLL consists of a
reservoir of proliferating cells within the bone marrow
and the lymph nodes and a pool of quiescent cells cir-
culating in the peripheral blood. L-selectin expression
in these two populations is largely different being
FIG. 4. Cell surface TACE and phosphorylated p38MAPK expression. Cell surface TACE expression was detected by ﬂow cytometry, the representative
histogram of panel A shows TACE expression of control B-cells and B-CLL cells. Results of TACE expression (panel B) were expressed as relative
ﬂuorescent intensities (RFI) in samples of controls (n = 18) and CLL patients (n = 30). In CLL samples, TACE RFI was signiﬁcantly lower (P < 0.0001)
compared to controls. The pp38MAPK was examined in permeabilized cells by ﬂow cytometry, the histogram of panel C shows pp38MAPK expression of
control B-cells and B-CLL cells. Results of controls (n = 11) and CLL patients (n = 19) were expressed as RFI (panel D). Malignant B cells showed
signiﬁcantly higher (P = 0.023) pp38MAPK levels compared to normal B-cells. [Color ﬁgure can be viewed at wileyonlinelibrary.com]
FIG. 5. Protein phosphatase activity of normal B-lymphocytes and
CLL cells. Phosphatase activity (PA) of B-cell lysates was assayed with
32P-MLC20 substrate and the released 32Pi was measured. Total and
PP2A phosphatase activity were determined and the results were
normalized for cell counts. Total phosphatase activity in normal-B cells
(n = 9) were regarded as 100%. Both total PA and PP2A were
signiﬁcantly lower in B-CLL (n = 24) compared to normal B-cells. The
results are displayed as the mean and standard deviation (SD).
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elevated in the former and decreased in the latter (9).
Previous works have demonstrated that the transen-
dothelial migration of lymphocytes in CLL is accompa-
nied by a downregulation of L-selectin on circulating
B-CLL cells (7) and it was also demonstrated that low
L-selectin expression on these cells is a negative prog-
nostic factor (20). In a recent publication (21), it was
also found, that L-selectin levels on T-lymphocytes in
chronic myeloid leukemia patients are associated with
the success of treatment, that is, low surface L-selectin
on T-cells and elevated soluble L-selectin levels were
found to be an unfavorable sign for tyrosine kinase
inhibitor treatment.
In our studies, we found in an observation cohort of
CLL patients that the low surface L-selectin expression
of B-CLL cells is accompanied by an elevated soluble
L-selectin level. The low surface expression was found
to be associated with the clinical status of the CLL
patients as determined by the Rai-stages. The soluble
L-selectin values were also signiﬁcantly elevated in
more advanced stages but evidently—when normalized
for the absolute lymphocyte count of the patients—
these values became actually lower.
In a separate investigative cohort, we performed a
stepwise evaluation for the investigation of decreased
surface L-selectin expression on B-CLL cells. We
hypothesized that the enhanced SET oncoprotein
described for B-CLL cells would result in a downregula-
tion of PP2A activity. Using a 32P-based phosphatase
activity assay with selective phosphatase inhibitor, we
veriﬁed that lysates of B-CLL cells possess signiﬁcantly
lower total phosphatase activity as well as PP2A activity
when compared to normal B-cells. Cytogenetic alter-
ations are frequent in CLL and the 11q deletion is an
unfavorable prognostic marker that may result in a
diminished PP2A acivity. In our investigative cohort of
B-CLL patients, we found that 11q deletion did not
inﬂuence the PP2A activities measured in cell lysates.
Other cell types in our cohort were also investigated
and T-cells from B-CLL patients were also shown to
display signiﬁcantly lower values compared to T-cells
of healthy individuals, although the differences were
considerably more subtle compared to that observed
between normal and leukemic B-cells. L-selectin
expression of neutrophils of B-CLL patients showed
no difference when compared to healthy individuals
(data not shown) although neutrophil soluble L-selectin
was detectable in samples with normal neutrophil
percentage.
The observed lower phosphatase activity can result
in an enhanced phosphorylation of downstream phos-
phoproteins. We found signiﬁcantly higher basic
pp38MAPK level in permeabilized B-CLL cells com-
pared to normal B-cells by ﬂow cytometric assay
(P = 0.023). We further investigated this phenomenon
using the phosphatase inhibitor CLA. As expected, after
CLA treatment the pp38MAPK level was elevated in a
dose-dependent manner in both groups but the
pp38MAPK level was higher in B-CLL cells compared to
normal B-cells at all investigated CLA concentrations.
The functional consequence of p38MAPK phosphoryla-
tion is the subsequent further phosphorylation of
numerous proteins one being the metalloprotease
TACE. In a work of Peschon and coworkers on mouse
embryos with non-functional TACE, it was found that
in addition to their inability to release TNF-α, the
L-selectin shedding of thymocytes from these mice was
FIG. 6. Effect of phosphatase inhibitor (CLA) and MAPK inhibitor
(SB203580) on the p38MAPK phosphorylation and L-selectin
shedding. Inhibition of serine/threonine phosphatases with CLA caused
phosphorylation of p38MAPK, the degree of phosphorylation was
slightly larger in B-CLL cells with increasing CLA concentrations (panel
A). These intracellular changes induced the downregulation of cell
surface L-selectin (panel B). Panel C displays results of in vitro
experiment in which control PBMCs were pretreated with MAPK
inhibitor before CLA treatment. CLA-induced shedding of L-selectin was
also attenuated at 5 nM CLA, in the presence of the MAPK inhibitor.
The results are the mean and standard deviation (SD) of three different
experiments.
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also drastically reduced that proved that TACE is
responsible for L-selectin shedding in this setting (22).
Detailed biochemical studies have revealed the associa-
tion of L-selectin shedding and TACE (23). The shed-
ding process involves the simultaneous decrease of
surface expression of both the shed protein (L-selectin)
as well as the sheddase TACE as has been described
previously (24). We also found a signiﬁcantly lower
expression of functional TACE on the surface of B-CLL
cells when compared to normal B-cells. It may be antic-
ipated that TACE downregulation would result in a suc-
ceeding signiﬁcant elevation of soluble form of TACE in
the plasma. However, this is not evidently the case as
we only observed a mild elevation of soluble TACE
(data not shown). This ﬁnding is in agreement with
previous results (24) where the authors also did not
detect soluble fragments of TACE in their THP1 and
Jurkat cell lines, but they observed that instead of
release to the medium the TACE was internalized upon
activation.
Because of the already diminished phosphatase activ-
ity, 5 nM CLA basically abrogated L-selectin expression
on B-CLL cells but only decreased L-selectin expression
by 50% on normal B-cells. This observation is also con-
sistent with the known high activity of kinases due to
the autonomous BCR activation in CLL. Overactive
kinases of CLL cells are losing their brake with
depressed phosphatase inhibition and release their
exaggerated effect on inhibition of L-selectin expres-
sion. This phosphatase inhibitor elicited L-selectin
downregulation was investigated using a highly speciﬁc
inhibitor of the p38MAPK, that prevented the CLA-
elicited pp38MAPK formation even in the presence of
relatively high CLA concentration and it also attenuated
the CLA-elicited L-selectin downregulation. L-selectin
shedding however is not restricted to the aforemen-
tioned processes, several pathophysiological stimuli
including as simple as oxidation–reduction processes
can modify cysteinyl sulfhydryl groups in the mature
TACE and may provide further means for regulating
L-selectin shedding (25).
In our both cohorts, we deliberately selected non-
treated CLL patients as we wanted to explore the
phenomena of adhesive protein expression and some
underlying mechanism. Studying adhesion protein
expression on CLL-cells may be extended to treatment
follow-up since there are several drugs that either
inhibit PP2A like FTY720 (26) or inhibit p38MAPK
activity like Rituximab (27).
Our ﬁndings have limitations, since we did not study
longitudinal changes of L-selectin expression and phos-
phorylation processes in CLL cases with or without
treatment and it is quite likely that low L-selectin
expression already occurs in monoclonal B-cell lym-
phocytosis (28). Furthermore, it also remains an
open question whether novel therapeutic agents like
ibrutinib and idelalisib therapy may affect L-selectin
expression or function as has been shown for an
adhesion receptor with prognostic signiﬁcance (29,30).
Nevertheless our data probably have pathophysiologi-
cal signiﬁcance as human soluble L-selectin at concen-
trations around 8,000 ng/mL completely inhibit L-
selectin mediated lymphocyte binding to activated
endothelial cells (31) and the migratory capabilities of
lymphocytes expressing lower surface L-selectin like in
B-CLL, can already be signiﬁcantly modiﬁed by soluble
L-selectin values of 5–6,000 ng/mL observed in our
samples.
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